Tenecteplasa intraarterial después de trombectomía endovascular para un accidente cerebrovascular por oclusión de grandes vasos (TNK-FLOW)
The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The primary objective of this study is to determine the safety and feasibility of intra-arterial Tenecteplase in selected patients with persistent post-thrombectomy hypoperfusion on computed tomography perfusion based on symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage producing decline from the initial NIHSS of ≥ 4 points) at 24-36 hours.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- Atrium Health Neurosciences Institute
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient/legally authorized representative has signed the Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- Functionally independent (modified Rankin scale 0-2) prior to presentation
- Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6
- Clinical syndrome consistent with occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (MCA), presenting within 4.5- to 24-hours of TLKW
- Evidence of ICA, MCA-M1, or MCA-M2 occlusion on baseline computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA). ICA/MCA tandem occlusions may be enrolled
- Alberta Stroke Program Early Computed Tomography Score ≥ 6 on pre-thrombectomy unenhanced CT as determined by treating neurologist or reading radiologist
- Pre-thrombectomy CTP or MRP with core infarction (cerebral blood flow < 30%) < 70 ml, mismatch ratio ≥ 1.8, mismatch volume ≥ 15 ml (completed within 120 minutes of skin puncture for thrombectomy). If skin puncture occurs more than 120 minutes after the pre-thrombectomy CTP, enrollment may proceed at the PI's discretion.
- Endovascular thrombectomy of ICA, MCA-M1 or MCA-M2 occlusion performed according to local standard of care, defined as at least completing the initial diagnostic angiogram
- CTP performed with RAPID AI AngioFlowTM within 30 minutes of thrombectomy completion
- Modified thrombolysis in cerebral infarction (mTICI) 2b-3 revascularization following endovascular thrombectomy (EVT) (or after initial diagnostic angiogram)
- Presence of Tm > 6 lesion on post-EVT CTP of adequate quality for interpretation in the distribution of the symptomatic occlusion
Exclusion Criteria:
- Current participation in another investigational drug or device study
- Known hypersensitivity or allergy to any ingredients of tenecteplase
- Active internal bleeding
- Known bleeding diathesis (e.g., Alzheimer's patients taking lecanemab)
- Systolic blood pressure > 185 mm Hg or diastolic blood pressure > 110 mm Hg after EVT, refractory to medical therapy
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 1.7
- Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)
- Treatment with a thrombolytic within the last 3 months prior to randomization
- Baseline platelet count < 100,000/mcL (results must be available prior to treatment)
- Baseline blood glucose > 400 mg/dL (22.20 mmol/L)
- Baseline blood glucose < 50 mg/dL; needs to be normalized prior to randomization
- Intracranial or intraspinal surgery or trauma within 2 months
- Intracranial malignant neoplasm, arteriovenous malformation, or unsecured aneurysm > 1 cm
- Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months
- History of acute ischemic stroke in the last 90 days
- History of hemorrhagic stroke
- Presumed septic embolus; suspicion of bacterial endocarditis
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed
- Pregnant
- Acute intracranial hemorrhage on pre-thrombectomy imaging or suspected acute intracranial hemorrhage after EVT
- Acute bilateral strokes on initial imaging
- Multiple acute intracranial occlusions (except ICA/MCA) on initial CTA or MRA
- Significant hemispheric mass effect or any amount of midline shift due to acute stroke
- Placement of cervical carotid or intracranial stent during thrombectomy procedure requiring dual antiplatelet therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Intra-arterial Tenecteplase
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial tenecteplase post-thrombectomy |
|
Comparador de placebos: Intra-arterial Saline
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial saline post-thrombectomy |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Participants with Change in Symptomatic Intracranial Hemorrhage
Periodo de tiempo: Hour 36
|
Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points. |
Hour 36
|
|
Participants with Parenchymal Hematoma Type 1
Periodo de tiempo: 24 Hours
|
Number of participants with parenchymal hematoma type 1 |
24 Hours
|
|
Participants with Parenchymal Hematoma Type 2
Periodo de tiempo: 24 Hours
|
Number of participants with parenchymal hematoma type 2 |
24 Hours
|
|
30-Day Mortality Count
Periodo de tiempo: Day 30
|
Number of patients expired |
Day 30
|
|
90-Day Mortality Count
Periodo de tiempo: Day 90
|
Number of patients expired |
Day 90
|
|
Number of Grade 3 Adverse Events
Periodo de tiempo: Hour 24
|
Total number of grade 3 adverse events |
Hour 24
|
|
Number of Grade 3 Adverse Events
Periodo de tiempo: Day 5
|
Total number of grade 3 adverse events |
Day 5
|
|
Number of Grade 3 Adverse Events
Periodo de tiempo: Day 30
|
Total number of grade 3 adverse events |
Day 30
|
|
Number of Grade 3 Adverse Events
Periodo de tiempo: Day 90
|
Total number of grade 3 adverse events |
Day 90
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of subjects achieving early neurological improvement
Periodo de tiempo: Hour 24
|
Proportion of subjects achieving early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Hour 24
|
|
Proportion of subjects achieving delayed neurological improvement
Periodo de tiempo: Day 30, Day 90
|
Proportion of subjects achieving delayed neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Day 30, Day 90
|
|
Ordinal Modified Rankin Scale score
Periodo de tiempo: Day 90
|
Modified Rankin scale scores range from 0-6. Higher score indicates greater disability. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-2 Points
Periodo de tiempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-2 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-1 Points
Periodo de tiempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-1 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-3 Points
Periodo de tiempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-3 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Change in Infarct Volume
Periodo de tiempo: Hour 24
|
Change in infarct volume on follow up CT or MRI |
Hour 24
|
|
Barthel Index Score
Periodo de tiempo: Day 90
|
Number of participants with Barthel Index score ≥ 95. |
Day 90
|
|
Median EuroQol-5-Dimension (EQ-5D) Index
Periodo de tiempo: Day 90
|
Median EuroQol-5-Dimension (EQ-5D) index has a score range of -0.573 to 1. Higher score indicates better quality score. |
Day 90
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Rahul Karamchandani, MD, Atrium Health Neurosciences Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Hemorragia
- Embolia y Trombosis
- Condiciones Patológicas, Signos y Síntomas
- Accidente cerebrovascular isquémico
- Carrera
- Trombosis
- Hemorragias intracraneales
Otros números de identificación del estudio
Otros números de identificación del estudio
- IRB00121066
- 40010317 (Otro identificador: Genentech, Inc)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .